Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

We recently compiled a list of the 11 Best Stocks To Invest In For Grandchildren. In this article, we are going to take a ...

It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...

Lilly upgraded its 2025 guidance to between $58 billion to $61 billion, slightly higher than Wall Street expectations by $1 ...

Eli Lilly stock is higher Thursday after the pharma giant beat fourth-quarter profit expectations and issued strong 2025 ...

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

Fred Alger Management, an investment management company, released its “Alger Spectra Fund” fourth quarter 2024 investor ...

Ratings has upgraded the issuer rating and senior unsecured notes ratings of global pharmaceutical company Eli Lilly and ...

Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.

In a report released today, Geoff Meacham from Citi maintained a Buy rating on Eli Lilly & Co (LLY – Research Report). The company’s shares ...

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...